Watanabe Toshiaki, Itabashi Michio, Shimada Yasuhiro, Tanaka Shinji, Ito Yoshinori, Ajioka Yoichi, Hamaguchi Tetsuya, Hyodo Ichinosuke, Igarashi Masahiro, Ishida Hideyuki, Ishihara Soichiro, Ishiguro Megumi, Kanemitsu Yukihide, Kokudo Norihiro, Muro Kei, Ochiai Atsushi, Oguchi Masahiko, Ohkura Yasuo, Saito Yutaka, Sakai Yoshiharu, Ueno Hideki, Yoshino Takayuki, Boku Narikazu, Fujimori Takahiro, Koinuma Nobuo, Morita Takayuki, Nishimura Genichi, Sakata Yuh, Takahashi Keiichi, Tsuruta Osamu, Yamaguchi Toshiharu, Yoshida Masahiro, Yamaguchi Naohiko, Kotake Kenjiro, Sugihara Kenichi
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan,
Int J Clin Oncol. 2015 Apr;20(2):207-39. doi: 10.1007/s10147-015-0801-z. Epub 2015 Mar 18.
Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men. Many new methods of treatment have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2014 for treatment of colorectal cancer (JSCCR Guidelines 2014) have been prepared as standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients by making these guidelines available to the general public. These guidelines have been prepared as a result of consensuses reached by the JSCCR Guideline Committee on the basis of careful review of evidence retrieved by literature searches and taking into consideration the medical health insurance system and actual clinical practice in Japan. They can, therefore, be used as a guide for treating colorectal cancer in clinical practice. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions of the Guideline Committee, controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories, on the basis of consensus reached by Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2014.
在日本,结直肠癌是主要的死亡原因之一,在女性恶性肿瘤死亡病例中占比最高,在男性中位列第三。近几十年来,研发出了许多新的治疗方法。《日本结直肠癌学会2014年结直肠癌治疗指南》(JSCCR指南2014)已制定完成,作为结直肠癌的标准治疗策略,以消除各机构之间的治疗差异,消除不必要的治疗和治疗不足的情况,并通过向公众公开这些指南,加深医护人员和患者之间的相互理解。这些指南是日本结直肠癌学会指南委员会在仔细审查文献检索所得证据的基础上,达成共识后制定的,同时考虑了日本的医疗保险制度和实际临床实践情况。因此,它们可作为临床实践中治疗结直肠癌的指南。更具体地说,它们可作为从患者处获得知情同意以及为每位患者选择治疗方法的指南。经过指南委员会的讨论,有争议的问题被选为临床问题,并给出了相应建议。每项建议都附有证据分类和推荐类别分类,这是基于指南委员会成员达成的共识。在此,我们呈现《日本结直肠癌学会2014年结直肠癌治疗指南》的英文版。